Early treatment effects after TBI

CAPTAIN – Safety and Efficacy of Cerebrolysin® in Neurorecovery after moderate-severe Traumatic Brain Injury

Muresanu, Dafin F, et al., „Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.” Neurological Sciences: 1-11

The effective treatment after TBI
- Early treatment effects
- Significantly reduced depression
- Improvement of memory and concentration

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.
**Treat with Cerebrolysin® as soon as possible after TBI**

**Beneficial effects already on day 10**
- Early independence
- Patients are less dependent on caregivers early on
- High potential for earlier discharge

![Graph showing beneficial effects](image)

- Superiority of Cerebrolysin® already after 10 days
- 6 out of 7 single outcome scales showing the superiority of Cerebrolysin already on day 10
- Already one early treatment cycle brings medium superiority even on day 30

**Title:** Efficacy and safety of Cerebrolysin® in Neurorecovery after moderate-severe traumatic brain injury: Results from the CAPTAIN II trial

**Patients:** 80 Cerebrolysin® group + 59 Placebo group = 139 patients in total

**Treatment:**
- Treatment Cycle 1 = Day 1 – 10: 50 ml/day
- Treatment Cycle 2 = Day 31 – 40: 10 ml/day
- Treatment Cycle 3 = Day 61 – 70: 10 ml/day

---

**Copyright © 2020 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria.**

**ABREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition:**

One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection.

**Therapeutic indications:** Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer’s type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion.

**Contraindications:** Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdosage, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 1.0/Jan 28 2014)